Table 2.
Compilation of HLA-A2 peptides tested for recognition by CD8+ effector T cells
| Antigen | aa position | aa sequence | Reference nos |
|---|---|---|---|
| HPV16 | |||
| ″E7 | 11–19 | YMLDLQPET | [24], [25], [28] |
| ″E7 | 73–81 | HVDIRTLED | |
| ″E7 | 82–90 | LLMGTLGIV | |
| ″E7 | 85–93 | GTLGIVCPI | |
| M. tuberculosis | |||
| ″Ag 19 kDa | 88–97 | VLTDGNPPEV | [29] |
| ″Ag85A | 48–56 | GLPVEYLQV | [30] |
| ″Ag85A | 242–250 | KLIANNTRV | |
| ″Ag85B | 143–152 | FIYAGSLSAL | [31] |
| ″Ag85B | 199–207 | KLVANNTRL | |
HLA-A2 binding peptides from HPV16 E7 or from antigens associated with M. tuberculosis have been described. Until now, only in vitro expanded T cell lines have been shown to react with HPV16-E7 associated epitopes.